Private Investment Opportunity
A near-complete South African production facility designed for GACP and EU-GMP export into UK and European medical markets.
Targeting a structured return through a secured loan component with additional equity upside. The raise is designed to complete a late-stage pharmaceutical facility with tangible asset backing.
Structure: Secured loan + 10% equity participation. Asset backing through privately owned land and physical facility near Rustenburg, South Africa.
A late-stage pharmaceutical cultivation facility with tangible asset backing. Located on privately owned land near Rustenburg, South Africa.
The head house is completed, grow room pads are in place, and the facility has been designed with EU-GMP export standards in mind. The business is positioned as a regulated pharmaceutical supply-chain asset rather than a speculative cultivation start-up.
The facility is designed to reach first revenue shortly after completion and initial GACP approval.
European prescription medical markets continue to require consistent, compliant supply. The opportunity is to complete a lower-cost South African production base capable of serving international medical markets under GACP standards and, in due course, EU-GMP certification.
European markets face limited compliant pharmaceutical supply, creating a structural opportunity for certified producers.
South African production costs are significantly lower than European equivalents, enabling competitive pricing in premium export markets.
GACP certification provides immediate market access, with EU-GMP certification unlocking higher-value pricing tiers.
🛡️ Significant capital already deployed reduces development risk — ~£3.5M invested to date.
🏢 Physical asset backing through land and facility provides downside protection for investors.
📈 Lower-cost South African production with access to higher-value EU markets creates a compelling margin structure.
✓ Clear value uplift through EU-GMP certification, enabling access to premium pricing tiers.
🌍 Experienced local operators with regulatory expertise and a responsible pharmacist supporting the compliance pathway.
→ Positioned within a growing global pharmaceutical supply chain with defined export market relationships.
The £2.5M raise is allocated to defined completion milestones, each directly tied to project progression and regulatory advancement.
Total Raise
£2.5M
Secured loan + 10% equity participation
Grow Room Completion
Finalise construction of grow rooms to operational standard.
Infrastructure & Utilities
Final infrastructure, power, water, and environmental systems.
Licensing & Compliance
Regulatory submissions, legal structuring, and compliance pathway.
Working Capital
Operational capital to support first production cycle.
GACP & EU-GMP Certification
Progression through certification to unlock export market access.
We are currently engaging with a limited number of investors and capital partners to complete this raise.
Full investment materials, including financial model and technical details, are available upon request.
Request Full Investment Pack →For further information or to request the full investment pack, please contact us directly. We are engaging with a limited number of investors at this stage.
Full investment materials including financial model, technical details, and legal structure are available to qualifying investors upon request.
For sophisticated, high-net-worth and professional investors only.